Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (NASDAQ: ABCL) closed the day trading at $3.51 down -3.04% from the previous closing price of $3.62. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 1.68 million shares were traded. ABCL stock price reached its highest trading level at $3.635 during the session, while it also had its lowest trading level at $3.51.
Ratios:
For a better understanding of ABCL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.75 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1032129600 and an Enterprise Value of 407717792. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.84 while its Price-to-Book (P/B) ratio in mrq is 0.91. Its current Enterprise Value per Revenue stands at 11.393 whereas that against EBITDA is -2.004.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $8.05, while it has fallen to a 52-week low of $3.58. The 50-Day Moving Average of the stock is -12.22%, while the 200-Day Moving Average is calculated to be -25.33%.
Shares Statistics:
Over the past 3-months, ABCL traded about 1.26M shares per day on average, while over the past 10 days, ABCL traded about 1429760 shares per day. A total of 290.82M shares are outstanding, with a floating share count of 206.02M. Insiders hold about 29.94% of the company’s shares, while institutions hold 38.64% stake in the company. Shares short for ABCL as of 1715731200 were 19748393 with a Short Ratio of 15.71, compared to 1713139200 on 23091848. Therefore, it implies a Short% of Shares Outstanding of 19748393 and a Short% of Float of 8.7299995.
Earnings Estimates
The current rating of AbCellera Biologics Inc (ABCL) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.16, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.13 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.52 and -$0.64 for the fiscal current year, implying an average EPS of -$0.57. EPS for the following year is -$0.62, with 5.0 analysts recommending between -$0.42 and -$0.78.
Revenue Estimates
8 analysts predict $10.15M in revenue for the current quarter. It ranges from a high estimate of $11.57M to a low estimate of $7.75M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $10.06MFor the next quarter, 8 analysts are estimating revenue of $10.89M. There is a high estimate of $15.14M for the next quarter, whereas the lowest estimate is $7.7M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $53.64M, while the lowest revenue estimate was $33.4M, resulting in an average revenue estimate of $41.49M. In the same quarter a year ago, actual revenue was $38.02MBased on 5 analysts’ estimates, the company’s revenue will be $52.63M in the next fiscal year. The high estimate is $68.7M and the low estimate is $37.7M.
